The information in the site is intended for non-US healthcare professionals. For US healthcare professionals please visit www.rituxan.com
Welcome to MabThera.com
MabThera.com is a comprehensive resource for healthcare professionals outside the US who are interested in MabThera and the treatment of lymphomas. This site provides detailed information on MabThera, monoclonal antibody therapy, and treatment strategies for NHL and CLL.
About CLL
Here you can learn more about CLL, including current theories relating to disease aetiology and current practice in diagnosis and classification.
Treating CLL
Traditionally CLL has been considered an incurable disease and short-term responses were considered the best markers of therapy success.
About NHL
Here you can learn more about NHL, including current theories relating to disease etiology and current practice in diagnosis and classification.
Treating NHL
MabThera in combination with chemotherapy is the standard of care in NHL, offering patients with follicular disease prolonged survival and years of life free from relapse and allowing the best chance of a cure in diffuse large B cell lymphoma.
MabThera product characteristics
Find out more about the characteristics of MabThera and how it is used in the treatment of non-Hodgkin's lymphoma.
- The information on this website is not country-specific and may contain information that is outside the approved label in the country where you are located.
- © 2009 F. Hoffmann-La Roche Ltd.